Urology
Volume 75, Issue 6 , Pages 1358-1363, June 2010

Impact of Tadalafil Once Daily in Men With Erectile Dysfunction—Including a Report of the Partners' Evaluation

  • Stanley E. Althof

      Affiliations

    • Center for Marital and Sexual Health of South Florida, West Palm Beach, Florida
    • Corresponding Author InformationReprint requests: Stanley E. Althof, Ph.D., Center for Marital and Sexual Health of South Florida, 1515 North Flagler Drive, Suite 540, West Palm Beach, FL 33401
  • ,
  • Eusebio Rubio-Aurioles

      Affiliations

    • Asociación Mexicana para la Salud Sexual, Tlalpan, Brasília, Mexico
  • ,
  • Sheryl Kingsberg

      Affiliations

    • Case Western Reserve University School of Medicine, Cleveland, Ohio
  • ,
  • Haoyue Zeigler

      Affiliations

    • Lilly, United States, LLC, Indianapolis, Indiana
  • ,
  • David G. Wong

      Affiliations

    • Lilly, United States, LLC, Indianapolis, Indiana
  • ,
  • Patrick Burns

      Affiliations

    • Lilly, United States, LLC, Indianapolis, Indiana

Received 21 July 2009; accepted 14 November 2009. published online 08 March 2010.

Objectives

To evaluate the effect of tadalafil 5 mg taken once daily on efficacy (erection achievement and penetration) and overall sexual satisfaction in men with erectile dysfunction (ED) and their female partners.

Methods

This retrospective analysis included data pooled from 2 multicenter, randomized, double-blind, placebo-controlled trials that included 505 couples (tadalafil, n = 373; placebo, n = 132) in which the men received tadalafil 5 mg once daily or placebo for 12 weeks. Individual Sexual Encounter Profile (SEP) diaries were completed independently by the male subject and his female partner after each sexual intercourse attempt. The mean per-subject/per-partner percentage of “yes” responses to SEP diary questions were assessed, as was agreement between subjects' and partners' responses.

Results

Subjects and partners in the tadalafil-treated group reported significantly greater improvements in the man's ability to achieve some erection, vaginal penetration, and overall sexual satisfaction compared with the placebo-treated group (P < .001). For all intercourse attempts, the mean per-couple percentage of agreement for those in the tadalafil and placebo groups, respectively, was high for erection achievement (99.0% and 96.6%), vaginal penetration (98.6% and 97.4%), and overall satisfaction (84.3% and 82.8%).

Conclusions

Tadalafil 5 mg taken once daily as treatment for ED improved overall satisfaction for men and their female partners. This analysis demonstrates the high concordance among couples in their responses to the man's treatment for ED.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by Lilly, United States, LLC, including assistance with manuscript preparation provided by Danette Hann, PhD (i3 Statprobe).

 Dr. Althof is consultant or adviser for Pfizer, Palitan, GSK, Eli Lilly, Boehringer-Ingelheim, Johnson and Johnson, Plethora and a Principal Investigator for Boehringer-Ingelheim and Plethora.

 Dr. Rubio-Aurioles is currently a consultant, investigator and speaker for Eli Lilly, Bayer Schering, Boehringer-Ingelheim, and More Pharma, Mexico.

 Dr. Kingsberg is an investigator for BioSante, Procter & Gamble, Boehringer-Ingelheim, a consultant for Wyeth and Boehringer-Ingelheim, on the speakers bureau for Eli Lilly, and has received honoraria from Johnson & Johnson.

 Mrs. Zeigler is an employee of Lilly USA, LLC.

 Dr. Wong and Dr. Burns are employees of Lilly, United States, LLC and own stock in the company.

PII: S0090-4295(09)03108-2

doi:10.1016/j.urology.2009.11.066

Urology
Volume 75, Issue 6 , Pages 1358-1363, June 2010